title: Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: Two sides of the same coin.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Conti
authors.forename: Carlo
authors.initials: C
authors.lastname: Perricone
authors.forename: Fulvia
authors.initials: F
authors.lastname: Ceccarelli
authors.forename: Guido
authors.initials: G
authors.lastname: Valesini
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab